NMRA vs. VIR, DNA, TARS, BCRX, FDMT, SANA, AUTL, BEAM, CGEM, and CGON
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Tarsus Pharmaceuticals (TARS), BioCryst Pharmaceuticals (BCRX), 4D Molecular Therapeutics (FDMT), Sana Biotechnology (SANA), Autolus Therapeutics (AUTL), Beam Therapeutics (BEAM), Cullinan Therapeutics (CGEM), and CG Oncology (CGON). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology (NASDAQ:VIR) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
Vir Biotechnology presently has a consensus target price of $33.57, indicating a potential upside of 223.11%. Neumora Therapeutics has a consensus target price of $22.57, indicating a potential upside of 132.94%. Given Neumora Therapeutics' higher probable upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Neumora Therapeutics.
Vir Biotechnology received 30 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 48.78% of users gave Vir Biotechnology an outperform vote.
65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by company insiders. Comparatively, 26.4% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Neumora Therapeutics has a net margin of 0.00% compared to Neumora Therapeutics' net margin of -677.69%. Vir Biotechnology's return on equity of 0.00% beat Neumora Therapeutics' return on equity.
In the previous week, Vir Biotechnology had 13 more articles in the media than Neumora Therapeutics. MarketBeat recorded 15 mentions for Vir Biotechnology and 2 mentions for Neumora Therapeutics. Vir Biotechnology's average media sentiment score of 1.26 beat Neumora Therapeutics' score of 0.45 indicating that Neumora Therapeutics is being referred to more favorably in the news media.
Neumora Therapeutics has lower revenue, but higher earnings than Vir Biotechnology.
Summary
Neumora Therapeutics beats Vir Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
